Physician profile
Anurag Gupta
NPI 1104828441
$869.05
in general payments reported to CMS, 2019-2025
19 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.92 · 2020: $16.77 · 2024: $304 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.09 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $165.90 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $112.37 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $106.90 | 2024-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.21 | 2024-2025 | Jardiance, Synjardy |
| Abbvie INC. | $55.02 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $45.40 | 2019-2020 | |
| Medtronic, INC. | $43.15 | 2025 | Minimed 780g |
| Radius Health, INC. | $40.37 | 2024-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $32.59 | 2024-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $32.28 | 2024 | |
| Sequel Med Tech, LLC | $29.08 | 2025 | Twiist |
| Pfizer INC. | $21.40 | 2024 | |
| Dexcom, INC. | $19.56 | 2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $19.50 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Recordati_rare_diseases_inc. | $15.23 | 2025 | Isturisa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $14.58 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $14.57 | 2025 | Nexletol |
| Corium, LLC | $14.48 | 2024 | Azstarys |
| Ascendis Pharma Endocrinology INC | $13.46 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anurag Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.